What's Happening?
A 2026 mini-review by Sano, summarized by Philip R Judge, BVSc MVS, in the Journal of Small Animal Practice, provides an evidence-based overview of cannabidiol (CBD) use in small animal practice. The review indicates that current evidence supports cautious,
selective use of CBD as an adjunctive therapy rather than a primary treatment for dogs and cats. Evidence is strongest for canine osteoarthritis and epilepsy, though further standardized clinical trials are needed to establish optimal dosing and long-term safety. For canine osteoarthritis, some randomized controlled trials report improvements in owner-reported pain and activity scores, but objective measures like gait analysis have not consistently improved. In refractory idiopathic epilepsy in dogs, adjunctive CBD has been associated with a reduction in seizure frequency, though responder rates vary. For cats, clinical data for osteoarthritis and behavior remain limited and preliminary. Oncology evidence for CBD is predominantly preclinical, with no direct clinical evidence supporting its use as an anticancer treatment in veterinary patients. Adverse effects are generally mild and transient, primarily gastrointestinal signs and somnolence, with increases in serum alkaline phosphatase activity noted in dogs without overt hepatic injury.
Why It's Important?
This comprehensive review is crucial for veterinarians and pet owners in the U.S. as it provides a much-needed evidence-based perspective on the growing trend of CBD use in pets. The findings highlight the importance of scientific rigor in evaluating therapeutic claims, especially in a market often driven by anecdotal evidence and consumer demand. By delineating where evidence is strongest (canine osteoarthritis and epilepsy) and where it is lacking (oncology, feline conditions), the review helps guide responsible clinical practice and informs pet owners about realistic expectations. The caution against using CBD as a primary treatment and the emphasis on its adjunctive role underscore the need for integrated veterinary care. Furthermore, the identification of mild adverse effects and the recommendation for monitoring liver function during prolonged administration are vital for ensuring patient safety and preventing potential complications.
What's Next?
The review explicitly calls for further research, including larger sample sizes, standardized formulations, dose-finding studies, longer-term safety assessments, and species-specific clinical trials for both dogs and cats. This indicates that the veterinary community will likely see an increase in structured research to fill the existing knowledge gaps. Clinicians are advised to use quality-controlled products with verified cannabinoid composition and to consider potential drug interactions, particularly those involving cytochrome P450 pathways. The ongoing need for objective outcome measures, beyond owner-reported improvements, will drive future study designs. As more evidence emerges, guidelines for CBD use in small animal practice are expected to become more refined, leading to more precise and effective therapeutic applications.
Beyond the Headlines
The widespread interest in CBD for pets reflects a broader societal trend towards natural and alternative therapies, mirroring human health trends. However, the review underscores the critical difference between popular belief and scientific evidence. The discrepancy between subjective owner-reported improvements and objective clinical measures highlights the placebo effect, which can influence perceptions of efficacy in both human and veterinary medicine. The lack of direct clinical evidence for CBD in veterinary oncology, despite preclinical findings, serves as a reminder that promising laboratory results do not always translate directly to clinical success. This situation also brings to light regulatory challenges, as the market for pet CBD products often outpaces scientific validation, necessitating a cautious and evidence-based approach from veterinary professionals to protect animal welfare.
